Events, News, Presentations, Press Releases
Sutro Biopharma to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., February 6, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...
Events, News, Press Releases
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant...
Events, News, Presentations, Press Releases
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024 SOUTH SAN FRANCISCO, Calif., December 14, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a...
Events, News, Presentations, Press Releases
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 – Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and...
Events, News, Presentations, Press Releases
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit SOUTH SAN FRANCISCO, Calif., December 4, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...